
LLY
股票Eli Lilly and Co
LLY-USDT-SWAP
- 总部
- US
- 行业
- 制药
- 发行时间
- 1985-01-13
- 流通股
- 942M
区间表现
2 小时前52 周区间当前位于区间 87%
$623.782025-08-08
$1,149.102026-05-28
5 日+1.64%
本月至今-2.06%
13 周+2.87%
26 周+2.12%
年初至今+0.70%
52 周+46.71%
日均成交量 (10D)3.3M
日均成交量 (3M)3.2M
关键指标
2 小时前估值
- 市值
- $1.02T
- 企业价值
- $1.05T
- 市盈率 (TTM)
- 40.16
- 预期市盈率
- 27.51
- 市盈率 (年)
- 49.19
- PEG
- 1.37
- 市净率
- 38.29
- 市销率 (TTM)
- 14.05
- 市销率 (年)
- 15.58
- EV / EBITDA
- 31.38×
- EV / 营收
- 14.58×
- 每股收益 (TTM)
- $28.15
- 每股收益 (年)
- $22.95
- 基本每股收益 (TTM)
- $28.15
- 每股净资产
- $28.09
盈利能力
- 毛利率
- 82.83%
- 营业利润率
- 43.63%
- 净利率
- 34.99%
- 净资产收益率 (ROE)
- 101.31%
- 总资产收益率 (ROA)
- 22.73%
- 投资回报率 (ROI)
- 37.71%
- 每股 EBITDA
- $37.37
- 每股营收 (TTM)
- $80.64
成长性
- 营收增长 (TTM YoY)
- +47.44%
- 营收增长 (季 YoY)
- +55.55%
- EPS 增长 (TTM YoY)
- +128.83%
派息
- 股息率 (预期)
- 0.64%
- 股息率 (TTM)
- 0.55%
- 每股股息 (TTM)
- $5.91
- 派息率
- 22.10%
财务健康
- 流动比率
- 1.58
- 速动比率
- 0.78
- 负债权益比
- 1.60
- 长期负债权益比
- 1.54
风险
- Beta
- 0.52
- 波动率 (3M)
- 37.57%
分析师评级
2 小时前买入39 位分析师
评级期 2026-06-01强烈买入11
买入20
持有7
卖出1
强烈卖出0
财报
2 小时前上一季度超预期 +27.04%
2026 财年 Q1 · 2026-03-31
实际 EPS$8.55
预期 EPS$6.73
超预期额$1.82
下一次财报
2026-08-05
2026 财年 Q2
预期 EPS$8.90
预期营收$20.53B
相关新闻
2 小时前- CNBC·7 天前companyStocks making the biggest moves premarket: Ferrari, Lear, Intuitive Machines, Micron Technology and more
These are some of the stocks posting the largest moves in early trading.
- Benzinga·7 天前companyEli Lilly to Buy Curevo for Up to $1.5B, LimmaTech for $780M, Vaccine Company for $1.55B
Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand
- Benzinga·7 天前company'Lilly Agrees to Buys Trio of Vaccine Developers' - WSJ Exclusive
https://www.wsj.com/business/deals/lilly-agrees-to-buys-trio-of-vaccine-developers-cd5d50fa
- Yahoo·7 天前companyEli Lilly Stock Eyes Best Month This Year As Cholesterol, Obesity Drug Tailwinds Build
LLY's stock is still down year-to-date as AI-driven narratives have captured the bulk of investor attention and capital in 2026.
- Benzinga·7 天前companyChamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62%
Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.
- Yahoo·7 天前companyDon't Buy Viking Therapeutics Stock Until You Read This
It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.


